373 results match your criteria: "Sweden M.F.; Clinica Shaio[Affiliation]"
Targeting the Gut Microbiota of Vertically HIV-Infected Children to Decrease Inflammation and Immunoactivation: A Pilot Clinical Trial.
Nutrients
February 2022
Área de Enfermedades Infecciosas del Centro de Investigación Biomédica en Red del Instituto de Salud Carlos III (CIBERINFEC), Instituto de Salud Carlos III, 28029 Madrid, Spain.
Article Synopsis
- This study investigates the impact of nutritional supplementation on inflammation and immune function in HIV-infected children undergoing antiretroviral therapy (ART).
- A total of 24 children were randomly assigned to receive either a nutritional supplement combining symbiotics, omega-3/6 fatty acids, and amino acids or a placebo for four weeks.
- The results showed no significant changes in inflammatory or immune markers, but correlations between gut bacteria and immune responses suggest that the microbiota may play a role in modulating immune function in these children.
The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial.
Nat Med
March 2022
Institute of Heart Diseases, Medical University, Wroclaw, Poland.
The sodium-glucose cotransporter 2 inhibitor empagliflozin reduces the risk of cardiovascular death or heart failure hospitalization in patients with chronic heart failure, but whether empagliflozin also improves clinical outcomes when initiated in patients who are hospitalized for acute heart failure is unknown. In this double-blind trial (EMPULSE; NCT04157751 ), 530 patients with a primary diagnosis of acute de novo or decompensated chronic heart failure regardless of left ventricular ejection fraction were randomly assigned to receive empagliflozin 10 mg once daily or placebo. Patients were randomized in-hospital when clinically stable (median time from hospital admission to randomization, 3 days) and were treated for up to 90 days.
View Article and Find Full Text PDFIntegrating Quality Assurance and Quality Improvement With Guidelines: Systematic Stakeholder-Driven Development of an Extension of the Guidelines International Network-McMaster Guideline Development Checklist.
Ann Intern Med
May 2022
Department of Health Research Methods, Evidence, and Impact and Department of Medicine, McMaster University, Hamilton, Ontario, Canada, Institute for Evidence in Medicine, Medical Center and Faculty of Medicine, University of Freiburg, Freiburg, Germany, and Dipartimento di Scienze Biomediche, Humanitas University, Milan, Italy (H.J.S.).
Coxsackie B virus.
Trends Microbiol
June 2022
Center for Infectious Medicine, Department of Medicine Huddinge, Karolinska Institutet, Karolinska University Hospital Huddinge, Stockholm, Sweden. Electronic address:
Intravenous contrast medium extravasation: systematic review and updated ESUR Contrast Media Safety Committee Guidelines.
Eur Radiol
May 2022
Université de Paris, AP-HP, Hôpital Européen Georges Pompidou, DMU Imagina, Service de Radiologie, 20 Rue LeBlanc, 75015, Paris, France.
Need For A Review: Guidelines for management and prevention of contrast media extravasation have not been updated recently. In view of emerging research and changing working practices, this review aims to inform update on the current guidelines.
Areas Covered: In this paper, we review the literature pertaining to the pathophysiology, diagnosis, risk factors and treatments of contrast media extravasation.
Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer.
N Engl J Med
February 2022
From Barts Cancer Institute, Queen Mary University of London, London (P.S.); International Breast Cancer Center, Quironsalud Group, and Vall d'Hebron Institute of Oncology, Barcelona (J.C.), and the Faculty of Biomedical and Health Sciences, Department of Medicine, Universidad Europea de Madrid (J.C.), and Ramon y Cajal University Hospital (M.G.), Madrid; the National Cancer Center Singapore, Duke-National University of Singapore Medical School, Singapore (R.D.); Yale School of Medicine, Yale Cancer Center, New Haven, CT (L.P.); the University of Texas Southwestern Medical Center (H.M.), and Baylor University Medical Center, Texas Oncology, U.S. Oncology Network (J.O.), Dallas, and Texas Oncology, U.S. Oncology Network, Austin (D.P.); the Breast Unit, Kliniken Essen-Mitte, Essen, Charité-Universitätsmedizin Berlin, the Department of Gynecology with Breast Center (S.K.) and the Breast Cancer Center, Helios Klinikum Berlin-Buch (M.U.), Berlin, the Institute of Pathology, Philipps-University Marburg and University Hospital Marburg, Marburg (C.D.), the Breast Center, Department of Obstetrics and Gynecology and Comprehensive Cancer Center Munich, LMU University Hospital, Munich (N.H.), and the Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-European Metropolitan Region of Nuremberg, University Hospital Erlangen, Erlangen (P.A.F.) - all in Germany; the Department of Oncology-Pathology, Karolinska Institutet, and Breast Cancer Center, Cancer Theme, Karolinska University Hospital, Karolinska Comprehensive Cancer Center, Solna, Sweden (J.B.); Samsung Medical Center, Sungkyunkwan University School of Medicine (Y.H.P.), Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine (S.-A.I.), and Asan Medical Center, University of Ulsan College of Medicine (J.-H.A.) - all in Seoul, South Korea; Westmead Breast Cancer Institute, Westmead Hospital and the University of Sydney (R.H.), and Royal North Shore Hospital (S.B.-H.) - both in Sydney; Hokkaido Cancer Center, Sapporo, Japan (M.T.); the Breast Unit, Champalimaud Clinical Center-Champalimaud Foundation, Lisbon (F.C.), and Instituto Português de Oncologia do Porto Francisco Gentil, Porto (M.F.) - both in Portugal; Compass Oncology, U.S. Oncology Network, Portland, OR (J.A.); Virginia Oncology Associates, U.S. Oncology Network, Norfolk (M.D.); Centre Jean-Perrin, Clermont-Ferrand, France (M.-A.M.-R.); McGill University, Segal Cancer Centre, Jewish General Hospital, Montreal (J.-F.B.); and Merck, Kenilworth, NJ (Y.D., K.T., G.A., V.K.).
Article Synopsis
- The study assessed the effect of adding pembrolizumab to neoadjuvant chemotherapy in patients with early triple-negative breast cancer, showing a significant increase in the rates of pathological complete response after surgery compared to the placebo group.
- A total of 1174 patients were randomly assigned to receive either pembrolizumab with chemotherapy or a placebo, followed by adjuvant therapy post-surgery, with the primary focus on event-free survival and safety.
- After 39.1 months of median follow-up, the event-free survival rate at 36 months was significantly higher at 84.5% for the pembrolizumab group compared to 76.8% for the placebo group, indicating better outcomes for those
Prognostic differences in long-standing vs. recent-onset dilated cardiomyopathy.
ESC Heart Fail
April 2022
Department of Molecular and Clinical Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
Aims: This study aimed to evaluate the outcome and prognostic factors in patients with dilated cardiomyopathy (DCM) and long-standing heart failure (LDCM) vs. recent-onset heart failure (RODCM).
Methods And Results: We compared 2019 patients with RODCM (duration <6 months, mean age 58.
Circulating Metabolome and White Matter Hyperintensities in Women and Men.
Circulation
April 2022
The Hospital for Sick Children (E.S., J.S., Z.P.), University of Toronto, Canada.
Background: White matter hyperintensities (WMH), identified on T2-weighted magnetic resonance images of the human brain as areas of enhanced brightness, are a major risk factor of stroke, dementia, and death. There are no large-scale studies testing associations between WMH and circulating metabolites.
Methods: We studied up to 9290 individuals (50.
Age-Stratified Risk of Cerebral Venous Sinus Thrombosis After SARS-CoV-2 Vaccination.
Neurology
February 2022
From the Departments of Neurology (K.K., A.v.d.M., M.S.v.K., J.M.C.) and Vascular Medicine (M.M.L.), Amsterdam University Medical Centers, University of Amsterdam, the Netherlands; Departments of Neurology (M.R.H., M.A.) and Hematology (J.A.K.H.), Inselspital, Bern University Hospital, University of Bern; Department of Neurology (K.J., E.L., T.T.), Sahlgrenska University Hospital; Department of Clinical Neuroscience (K.J., E.L., T.T.), Institute of Neuroscience and Physiology, Sahlgrenska Academy at University of Gothenburg, Sweden; Department of Neurology (J.P.), Helsinki University Hospital and University of Helsinki, Finland; Department of Internal Medicine (S.M.) and Radboud Institute of Health Sciences (S.M.), Radboud University Medical Center, Nijmegen, the Netherlands; National Institute for Health Research University College London Hospitals Biomedical Research Centre (M.M.L.), UK; University of Lille (C.C.), Inserm, CHU Lille, U1172-Lille Neuroscience and Cognition, France; Department of Clinical Epidemiology and Biostatistics (A.H.Z.), Amsterdam University Medical Centers, University of Amsterdam, the Netherlands; and Department of Neurosciences and Mental Health (J.M.F., D.A.d.S.), Neurology Service, Hospital de Santa Maria/Centro Hospitalar Universitário Lisboa Norte (CHULN), University of Lisbon, Portugal.
Background And Objectives: Cerebral venous sinus thrombosis (CVST) as a part of the thrombosis and thrombocytopenia syndrome is a rare adverse drug reaction of severe acute respiratory syndrome coronavirus disease 2 (SARS-CoV-2) vaccination. Estimated background rate of CVST with thrombocytopenia is 0.1 per million per month.
View Article and Find Full Text PDFIdiopathic inflammatory myopathies.
Nat Rev Dis Primers
December 2021
Clinical Research Branch, National Institute of Environmental Health Sciences, National Institutes of Health, Research Triangle Park, NC, USA
Idiopathic inflammatory myopathies (IIM), also known as myositis, are a heterogeneous group of autoimmune disorders with varying clinical manifestations, treatment responses and prognoses. Muscle weakness is usually the classical clinical manifestation but other organs can be affected, including the skin, joints, lungs, heart and gastrointestinal tract, and they can even result in the predominant manifestations, supporting that these are systemic inflammatory disorders. Different myositis-specific autoantibodies have been identified and, on the basis of clinical, histopathological and serological features, IIMs can be classified into several subgroups — dermatomyositis (including amyopathic dermatomyositis), antisynthetase syndrome, immune-mediated necrotizing myopathy, inclusion body myositis, polymyositis and overlap myositis.
View Article and Find Full Text PDFClonal Hematopoiesis Is Associated With Higher Risk of Stroke.
Stroke
March 2022
Department of Epidemiology (A.P.R.), University of Washington, Seattle.
Article Synopsis
- Clonal hematopoiesis of indeterminate potential (CHIP) is a new risk factor linked to higher chances of stroke, especially ischemic and hemorrhagic types, emphasizing its importance in understanding cardiovascular health.* -
- This study analyzed data from over 78,000 individuals to explore the connection between CHIP and stroke, finding significant associations even after accounting for age, sex, and race.* -
- The results indicated that certain mutated genes within CHIP were more strongly associated with different stroke types, suggesting that further research is necessary to understand these relationships better.*
Palmdelphin Regulates Nuclear Resilience to Mechanical Stress in the Endothelium.
Circulation
November 2021
Rudbeck, Beijer and SciLifeLab Laboratories, Department of Immunology, Genetics and Pathology (M.S.-J., R.O.S., Y.J., S.N., Y.D., P.A., M.H., L.C.-W.), Uppsala University, Sweden.
Background: PALMD (palmdelphin) belongs to the family of paralemmin proteins implicated in cytoskeletal regulation. Single nucleotide polymorphisms in the locus that result in reduced expression are strong risk factors for development of calcific aortic valve stenosis and predict severity of the disease.
Methods: Immunodetection and public database screening showed dominant expression of PALMD in endothelial cells (ECs) in brain and cardiovascular tissues including aortic valves.
Associations of Disease-Modifying Therapies With COVID-19 Severity in Multiple Sclerosis.
Neurology
November 2021
From the CORe (S.S.-Y., T.K.), Department of Medicine, and Neuroepidemiology Unit (S.S.-Y., N.N., A.F.), Melbourne School of Population & Global Health, University of Melbourne, Parkville, Australia; Menzies Institute for Medical Research (S.S.-Y.), University of Tasmania, Hobart, Australia; ESAT-STADIUS (E.D.B., Y.M., A.P.), KU Leuven, Belgium; Department of Neurology (T.K.), Melbourne MS Centre, Royal Melbourne Hospital, Parkville, Australia; MS International Federation (N.R., C.W.), London, UK; Department of Clinical Neuroscience (J.A.H., T.S., L.F., A.G.), Swedish MS Registry, Stockholm, Sweden; Department of Neurology (G.E.), CHU Pontchaillou, Rennes, France; Karolinska Institutet (T.S.), Solna, Sweden; Biomedical Research Institute-Data Science Institute (L.G., A.P., L.P.), Hasselt University, Belgium; Department of Medical Informatics (T.P.), University Medical Center Göttingen, Germany; Department of Computer Science and AI (C.G.), KU Leuven, Belgium; QMENTA (N.L.), Barcelona, Spain; Medpace Reference Laboratories (A.A.), Molecular Unit, Leuven, Belgium; iConquerMS People-Powered Research Network (R. McBurney, H.S.), Accelerated Cure Project for MS, Waltham, MA; NeuroTransData Study Group (A.B.B., S.B.), NeuroTransData, Neuburg, Germany; German MS-Register by the National MS Society (A. Stahmann), MS Forschungs- und Projektentwicklungs-gGmbH, Hannover, Germany; UK MS Register (R. Middleton, R.S.N.), Swansea University, UK; COViMS (A. Salter, R.J.F.), US; Division of Biostatistics (A. Salter), Washington University in St. Louis, St Louis, MO; Mellen Center for Multiple Sclerosis (R.J.F.), Cleveland Clinic, Cleveland, OH; Department of Neuroscience (A.v.d.W., H.B.), Central Clinical School, Monash University, Melbourne, Australia; Al-Amiri Hospital (R.A.), Kuwait City, Kuwait; Dokuz Eylul University (S.O.), Izmir, Turkey; Neurology Department (J.I.R.), Hospital Universitario de CEMIC; RELACOEM (J.I.R., R.N.A.), Buenos Aires, Argentina; Australian MS Longitudinal Study (I.v.d.M.), Menzies Institute for Medical Research, University of Tasmania, Hobart, Australia; Bulgarian SmartMS COVID-19 Dataset (R.I.), Sofia, Bulgaria; ABEM-Brazilian MS Patients Association (G.S.d.O., A.E.D.), São Paulo, Brazil; Danish Multiple Sclerosis Registry (M.M.), Department of Neurology, University Hospital Rigshospitalet, Glostrup, Denmark; Universidade Estadual Paulista (D.B.), Unesp, Faculdade de Medicina, Botucatu, Brazil; REDONE.br-Brazilian Registry of Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorders (D.B., M.F.M.); Irmandade da Santa Casa de Misericórdia de São Paulo (M.F.M.), Brazil; Multiple Sclerosis University Center (R.N.A.), Ramos Mejia Hospital-EMA, Buenos Aires, Argentina; Imperial College London (R.S.N.); Swansea University (R.S.N.), Swansea, UK; Mental Health Area (J.B.); MS and Demyelinating Diseases (A.S.C.)., Hospital Británico de Buenos Aires, EMA, Argentina; Servei de Neurologia-Neuroimmunologia (A.Z., G.A.), Centre d'Esclerosi Múltiple de Catalunya, (Cemcat); Vall d'Hebron Institut de Recerca (A.Z., G.A.), Vall d'Hebron Hospital Universitari; Universitat Autònoma de Barcelona (A.Z., G.A.), Spain; and Institute of Experimental Neurology (G.C.), Ospedale San Raffaele, Milan, Italy.
Background And Objectives: People with multiple sclerosis (MS) are a vulnerable group for severe coronavirus disease 2019 (COVID-19), particularly those taking immunosuppressive disease-modifying therapies (DMTs). We examined the characteristics of COVID-19 severity in an international sample of people with MS.
Methods: Data from 12 data sources in 28 countries were aggregated (sources could include patients from 1-12 countries).
New Creatinine- and Cystatin C-Based Equations to Estimate GFR without Race.
N Engl J Med
November 2021
From the Division of Nephrology (L.A.I., S.J.C., A.S.L.) and the Institute for Clinical Research and Health Policy Studies (H.T.), Tufts Medical Center, Tufts Clinical and Translational Science Institute, Tufts University (H.T.), the Section on Genetics and Epidemiology, Joslin Diabetes Center (A.D.), and the Department of Medicine, Harvard Medical School (A.D.) - all in Boston; the Renal-Electrolyte and Hypertension Division, Perelman School of Medicine (N.D.E.), and the Departments of Biostatistics, Epidemiology, and Informatics, Center for Clinical Epidemiology and Biostatistics (W.Y.), University of Pennsylvania, Philadelphia; the Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health and the Welch Center for Prevention, Epidemiology, and Clinical Research, Johns Hopkins Medical Institutions (J.C., D.W., Y.S., M.E.G., E.S., S.H.B.), the Division of Nephrology, Department of Medicine, Johns Hopkins University School of Medicine (D.C.C., M.E.G.), and the Department of Medicine, Division of Nephrology, University of Maryland School of Medicine (R.K.) - all in Baltimore; the Kidney Health Research Collaborative, San Francisco Veterans Affairs (VA) Medical Center and University of California, San Francisco (M.M.E., M.G.S.), the Division of Nephrology, Department of Medicine, San Francisco VA Health Care System and University of California, San Francisco (M.M.E.), and the Department of Medicine, Priscilla Chan and Mark Zuckerberg San Francisco General Hospital and University of California, San Francisco (N.R.P.) - all in San Francisco; the Clinical Trial Unit, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland (M.F.); the Division of Biostatistics, Department of Population Health Sciences, University of Utah Health, Salt Lake City (T.G.); the Department of Clinical Chemistry and Pharmacology, Institute of Laboratory Medicine, Lund University, Lund, Sweden (A.G.); the Faculty of Medicine, University of Iceland, Reykjavik, and the Icelandic Heart Association, Kopavogur - both in Iceland (V.G.); the Departments of Medicine and Epidemiology, University of Alabama at Birmingham, Birmingham (O.M.G.); the Departments of Laboratory Medicine and Pathology (A.B.K., J.C.S.), Pediatrics (M.M.), and Medicine (M.M.), University of Minnesota, Minneapolis, and the Division of Nephrology and Hypertension, Mayo Clinic, Rochester (A.D.R., V.E.T.) - all in Minnesota; the Faculty of Medical Sciences, University Medical Center Groningen, Groningen, the Netherlands (G.N.); the Chronic Kidney Disease Section, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Phoenix, AZ (R.G.N.); the Department of Nephrology and Hypertension, Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland (E.D.P.); Rush University Medical Center, Chicago (R.R.); and Steno Diabetes Center Copenhagen and the Department of Clinical Medicine, University of Copenhagen - both in Copenhagen (P.R.).
Background: Current equations for estimated glomerular filtration rate (eGFR) that use serum creatinine or cystatin C incorporate age, sex, and race to estimate measured GFR. However, race in eGFR equations is a social and not a biologic construct.
Methods: We developed new eGFR equations without race using data from two development data sets: 10 studies (8254 participants, 31.
Oral delivery of systemic monoclonal antibodies, peptides and small molecules using gastric auto-injectors.
Nat Biotechnol
January 2022
Department of Chemical Engineering and David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA.
Article Synopsis
- Oral drug administration is typically limited by poor absorption and quick breakdown in the digestive system, necessitating injections for effective delivery.
- A new orally dosed liquid auto-injector has been developed, allowing for up to 4 mg doses of a bioavailable drug with injection-like absorption rates and achieving up to 80% bioavailability in just 30 minutes.
- Tests on swine show this method effectively delivers clinically relevant doses of commonly injected drugs, highlighting its potential for real-world medical applications.
Phospholamban antisense oligonucleotides improve cardiac function in murine cardiomyopathy.
Nat Commun
August 2021
Department of Cardiology University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
Heart failure (HF) is a major cause of morbidity and mortality worldwide, highlighting an urgent need for novel treatment options, despite recent improvements. Aberrant Ca handling is a key feature of HF pathophysiology. Restoring the Ca regulating machinery is an attractive therapeutic strategy supported by genetic and pharmacological proof of concept studies.
View Article and Find Full Text PDFPoint-of-care microvolume cytometer measures platelet counts with high accuracy from capillary blood.
PLoS One
December 2021
rHEALTH, Bedford, Massachusetts, United States of America.
Background: Point-of-care (PoC) testing of platelet count (PLT) provides real-time data for rapid decision making. The goal of this study is to evaluate the accuracy and precision of platelet counting using a new microvolume (8 μL), absolute counting, 1.5 kg cytometry-based blood analyzer, the rHEALTH ONE (rHEALTH) in comparison with the International Society of Laboratory Hematology (ISLH) platelet method, which uses a cytometer and an impedance analyzer.
View Article and Find Full Text PDFLigand-Independent G Protein-Coupled Estrogen Receptor/G Protein-Coupled Receptor 30 Activity: Lack of Receptor-Dependent Effects of G-1 and 17-Estradiol.
Mol Pharmacol
September 2021
Department of Experimental Medical Science (J.T., E.G.d.V., K.S., I.A.E., S.B., L.M.F.L.-L.) and Department of Clinical Sciences Lund, Division of Pediatrics and Wallenberg Centre of Molecular Medicine (R.K.) and Division of Cardiology (B.O.), Lund University, Lund, Sweden
G protein-coupled receptor 30 (GPR30) is a membrane receptor reported to bind 17-estradiol (E2) and mediate rapid nongenomic estrogen responses, hence also named G protein-coupled estrogen receptor. G-1 is a proposed GPR30-specific agonist that has been used to implicate the receptor in several pathophysiological events. However, controversy surrounds the role of GPR30 in G-1 and E2 responses.
View Article and Find Full Text PDFCurriculum for ERCP and endoscopic ultrasound training in Europe: European Society of Gastrointestinal Endoscopy (ESGE) Position Statement.
Endoscopy
October 2021
Department of Gastroenterology and Hepatology, University Hospitals Leuven, and TARGID, KU Leuven, Leuven, Belgium.
The European Society of Gastrointestinal Endoscopy (ESGE) has recognized the need to formalize and enhance training in endoscopic retrograde cholangiopancreatography (ERCP) and endoscopic ultrasound (EUS). This manuscript represents the outcome of a formal Delphi process resulting in an official Position Statement of the ESGE and provides a framework to develop and maintain skills in ERCP and EUS. This curriculum is set out in terms of the prerequisites prior to training; recommended steps of training to a defined syllabus; the quality of training; and how competence should be defined and evidenced before independent practice.
View Article and Find Full Text PDFReliable and valid assessment of procedural skills in resuscitative endovascular balloon occlusion of the aorta.
J Trauma Acute Care Surg
October 2021
From the Copenhagen Academy for Medical Education and Simulation (CAMES), Centre for Human Resources and Education (M.E., L.K., M.B.S., M.F., L.R.), Capital Region of Denmark, København; Department of Clinical Medicine, Faculty of Health and Medical Sciences (M.E., L.L., L.K., M.T.), University of Copenhagen; Department of Radiology (L.L., M.T.), Copenhagen University Hospital Rigshospitalet, Copenhagen; The Mobile Emergency Care Unit, Department of Anaesthesiology and Intensive Care (S.M.), The Prehospital Research Unit (S.M.), Region of Southern Denmark, Odense University Hospital; Department of Regional Health Research (S.M.), University of Southern Denmark, Odense, Denmark; Department of Cardiothoracic and Vascular Surgery and Department of Surgery, Faculty of Life Science (T.H.), Örebro University Hospital, Örebro; Department of Clinical Sciences, Faculty of Medicine (H.L.), Lund University, Lund; Section of Interventional Radiology, Department of Surgery (H.L.), Helsingborg Hospital, Helsingborg, Sweden; Department of Radiology and Nuclear Medicine (E.S.), St. Olavs University Hospital, Trondheim, Norway; Department of Otorhinolaryngology, Head & Neck Surgery and Audiology (M.F.), and Department of Intensive Care (L.R.), Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark.
Background: Valid and reliable assessment of skills is essential for improved and evidence-based training concepts. In a recent study, we presented a novel tool to assess procedural skills in resuscitative endovascular balloon occlusion of the aorta (REBOA), REBOA-RATE, based on international expert consensus. Although expert consensus is a strong foundation, the performance of REBOA-RATE has not been explored.
View Article and Find Full Text PDFReproductive period and preclinical cerebrospinal fluid markers for Alzheimer disease: a 25-year study.
Menopause
July 2021
Neuropsychiatric Epidemiology Unit, Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, Sahlgrenska Academy, Centre for Ageing and Health (AGECAP) at the University of Gothenburg, Mölndal, Sweden.
Objective: The aim of the study was to examine the association between reproductive period, as an indicator of endogenous estrogen, and levels of cerebrospinal fluid (CSF) biomarkers for Alzheimer disease (AD).
Methods: A population-based sample of women from Gothenburg, Sweden was followed from 1968 to 1994 (N = 75). All women had natural menopause and were free from dementia.
Sex ratios at birth in Australia according to mother's country of birth: A national study of all 5 614 847 reported live births 1997-2016.
PLoS One
October 2021
Division of Occupational and Environmental Medicine, EPI@LUND (Epidemiology, Population studies, and Infrastructures at Lund University), Lund University, Lund, Sweden.
Objectives: Son preference and sex selective practices have resulted in a deficit of girls in several countries, primarily across Asia. Emerging evidence indicates that son preference survives migration to Western high-income countries. The objective of this study was to assess male-to-female (M/F) ratios at birth per mother's country of birth in Australia 1997-2016, in total and by parity, and by states/territories and over time.
View Article and Find Full Text PDFWhat Happened with Muscle Force, Dynamic Stability And Falls? A 10-Year Longitudinal Follow-Up in Adults with Myotonic Dystrophy Type 1.
J Neuromuscul Dis
February 2022
Occupational and Physiotherapy Department, Sahlgrenska University Hospital, Gothenburg, Sweden.
Article Synopsis
- Individuals with myotonic dystrophy type 1 (DM1) experience significant muscle force loss, especially in ankle muscles, and show a decrease in dynamic stability over a ten-year period.
- The study involved 34 participants and found that male patients reported more frequent falls compared to females, with a strong correlation between slower walking times and the number of falls experienced.
- Key factors linked to frequent falls include weak ankle dorsiflexors and slower walking speeds, indicating that monitoring these aspects could help manage fall risk in DM1 patients.
Adjuvant Olaparib for Patients with - or -Mutated Breast Cancer.
N Engl J Med
June 2021
From the Breast Cancer Now Toby Robins Research Centre, the Institute of Cancer Research (A.N.J.T.), and the Breast Cancer Now Unit, Guy's Hospital Cancer Centre, King's College London (A.N.J.T.), London, AstraZeneca, Cambridge (S.J.H., N.B.), and Frontier Science (Scotland), Kincraig (R.M.C., E.M.F., C.C.) - all in the United Kingdom; Dana-Farber Cancer Institute, Harvard Medical School (J.E.G., R.D.G.), Frontier Science Foundation (R.D.G.), and Harvard T.H. Chan School of Public Health (R.D.G.) - all in Boston; the Breast Oncology Institute, Chaim Sheba Medical Center, Tel Aviv University, Tel Aviv, Israel (B.K.); the University of Milan, European Institute of Oncology IRCCS, Milan (G.V.); Breast International Group (D.F., A.A.) and Institut Jules Bordet, l'Université Libre de Bruxelles (E.A., M.P.), Brussels; NRG Oncology (P.R., H.B., P.C.L., N.W., G.Y., C.E.G.) and the Basser Center for BRCA, Abramson Cancer Center, University of Pennsylvania (S.M.D.), Philadelphia, and the UPMC Hillman Cancer Center (P.R., P.C.L., N.W.) and the Department of Biostatistics (H.B., J.P.C., G.Y.), University of Pittsburgh, and the NSABP Foundation (N.W.), Pittsburgh - all in Pennsylvania; AstraZeneca, Gaithersburg (A.F.), and the National Cancer Institute, Rockville (L.A.K.) - both in Maryland; Vall d'Hebron Institute of Oncology and Vall d'Hebron University Hospital (J.B.) - both in Barcelona; BC Cancer, Vancouver, BC, Canada (K.A.G.); Sahlgrenska University Hospital (B.L.) and the Institute of Clinical Sciences, Department of Oncology, Sahlgrenska Academy, Gothenburg University (B.L.) - both in Gothenburg, Sweden; the Department of Oncology and Radiotherapy, Medical University of Gdańsk, Gdańsk (E.S.), the Maria Skłodowska-Curie National Research Institute of Oncology, Warsaw (Z.N.), the International Hereditary Cancer Center, Pomeranian Medical University, Szczecin (T.H.), and Read-Gene, Grzepnica (T.H.) - all in Poland; Kaiser Permanente Vallejo Medical Center, Vallejo (J.M.S.), and the UCLA Fielding School of Public Health, David Geffen School of Medicine at UCLA (P.A.G.), and the UCLA Jonsson Comprehensive Cancer Center (P.A.G.), Los Angeles - all in California; Fudan University Shanghai Cancer Center, Shanghai, China, (Z.S.); Georgia NCORP, Northside Hospital Cancer Institute (A.W.P.), and Piedmont Healthcare (A.W.P.) - both in Atlanta; German Breast Group, Neu-Isenburg (S.L.), the Center for Hematology and Oncology Bethanien and Goethe University, Frankfurt (S.L.), and the Center for Familial Breast and Ovarian Cancer and the Center for Integrated Oncology, Faculty of Medicine, University Hospital Cologne, Cologne (R.S.) - all in Germany; the Department of Internal Medicine I and Gaston H. Glock Research Center, Medical University of Vienna, Vienna (G.G.S.); Merck, Kenilworth, NJ (V.K.); the University of Queensland Centre for Clinical Research and Pathology Queensland (S.R.L.) - both in Brisbane, QLD, Australia; and Houston Methodist Cancer Center (C.E.G.) and Weill Cornell Medical College (C.E.G.) - both in Houston.
Background: Poly(adenosine diphosphate-ribose) polymerase inhibitors target cancers with defects in homologous recombination repair by synthetic lethality. New therapies are needed to reduce recurrence in patients with or germline mutation-associated early breast cancer.
Methods: We conducted a phase 3, double-blind, randomized trial involving patients with human epidermal growth factor receptor 2 (HER2)-negative early breast cancer with or germline pathogenic or likely pathogenic variants and high-risk clinicopathological factors who had received local treatment and neoadjuvant or adjuvant chemotherapy.
Secondary hyperparathyroidism, weight loss, and longer term mortality in haemodialysis patients: results from the DOPPS.
J Cachexia Sarcopenia Muscle
August 2021
Division of Nephrology, Endocrinology and Metabolism, Tokai University School of Medicine, Isehara, Japan.
Background: Wasting is a common complication of kidney failure that leads to weight loss and poor outcomes. Recent experimental data identified parathyroid hormone (PTH) as a driver of adipose tissue browning and wasting, but little is known about the relations among secondary hyperparathyroidism, weight loss, and risk of mortality in dialysis patients.
Methods: We included 42,319 chronic in-centre haemodialysis patients from the Dialysis Outcomes and Practice Patterns Study phases 2-6 (2002-2018).